FindTrial
Sign In

To study the benefits of addition of Cabergoline to Metformin in women with PCOS

To study the efficacy of Cabergoline as an adjunct to Metformin in management of overweight & obese women with PCOS

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/08/071776
Enrollment
100
Registered
2024-08-01
Start date
Unknown
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E282- Polycystic ovarian syndrome Health Condition 2: E282- Polycystic ovarian syndrome

Interventions

Intervention1: Tablet Cabergoline with Tablet Metformin: Tablet Cabergoline 0.5 mg once a week with Tablet Metformin 850 mg twice a day for 6 months Control Intervention1: Tablet Metformin: 850 mg twi

Sponsors

Nil
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Women diagnosed with PCOS by Rotterdam criteria, Age 16-35 years, BMI 23-35 kg/m2, Willing to participate in the study

Exclusion criteria

Exclusion criteria: Patients with other endocrine disorders such as Cushing’s Syndrome, acromegaly, pituitary adenoma, etc , Women planning pregnancy in next 6 months, Intolerability to cabergoline, Not willing to participate

Design outcomes

Primary

MeasureTime frame
Regularization of mensesTimepoint: 6 months—

Secondary

MeasureTime frame
Improvement in glycemic parameterTimepoint: 1, 3, 6 MONTHS;Reduction in serum inflammatory markersTimepoint: 1, 3, 6 months—

Countries

India

Contacts

Public ContactDr Mamta Choudhary

AIIMS, New Delhi

garimakachhawa2012@gmail.com9868246702

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026